Results of phase III trial of lebrikizumab in moderate-to-severe AD at 52 weeks, A. Blauvelt et al.

Author video for 'Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials' Full article: https://doi.org/10.1093/bjd/ljad022